NextCure, Inc.
9000 Virginia Manor Rd. Suite 200
Beltsville
MD
20705
United States
Tel: (240)399-4900
Website: https://www.nextcure.com/
Email: Info@NextCure.com
About NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. We view the immune system holistically and, rather than target one specific immune cell type, we focus on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. Through our proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology, or FIND-IO, platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. We are focused on patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies.
Cancer is a complex disease where cells in the tumor microenvironment promote tumor progression, immune evasion and suppression of anti-tumor immune responses. While therapies targeting inhibitory or immune checkpoint molecules have shown important success in many cancers, not all patients benefit from these therapies (non-responders), and many develop resistance after initial treatment. NextCure is identifying novel tumor-specific interactions and mechanisms of immune regulation to generate a sustainable product pipeline to address these patients in need.
NextCure brings significant experience and innovation in cancer immunology. The company’s FIND-IOTM technology provides a large repertoire of function-based screens and imparts a unique understanding of cell surface molecular interactions between immune and diseased cells. We are using this important knowledge to rapidly develop and advance novel biologics that impact suppressive myeloid cell populations, T cell subsets, and other cell populations within the tumor microenvironment to restore anti-tumor activity and improve clinical response rates and outcomes for patients.
Stock Symbol: NXTC
Business Spotlight - Nextcure
90 articles about NextCure, Inc.
-
Four biotech companies began trading on the Nasdaq this morning. Here's a look at today’s launches and one rumored IPO.
-
A summary of IPOs from companies in the biotech and pharma world since April 1, 2019.
-
Although 2018 marked a record year for biopharma initial public offerings (IPO), 2019 has had a number of IPOs so far as well. Here’s a look at four recent IPO filings—and $86 million appears to be the magic number.
-
New Haven, Conn.-based NextCure and the Yale University Office of Corporate Research (OCR) announced the publication of a study describing Siglec-15 (S15), a new target for immunotherapy. The article was published in the journal Nature Medicine.
-
NextCure Announces Formation of Scientific Advisory Board to Guide Development of its Portfolio of Immunomedicines
2/12/2019
NextCure, Inc., announced the appointment of renowned researchers and thought leaders with expertise in immunology, oncology and drug development to a newly formed scientific advisory board.
-
New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.
-
NextCure Raises $93 Million in Series B Financing
11/13/2018
-- Proceeds Will Advance Growing Portfolio of Novel Immunomedicine Drug Candidates --
-
NextCure to Present Preclinical Data on NC318, a Novel Immunomedicine Targeting Siglec-15, at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
11/8/2018
NextCure, Inc. today announced that preclinical data supporting the development of its lead drug candidate, NC318, will be presented in a poster session at the Society for Immunotherapy of Cancer 33rd Annual Meeting being held November 7th – 11th 2018 in Washington, D.C.
-
Lilly is paying NextCure $25 million upfront. NextCure will be eligible for various development and commercial milestone payments, as well as royalties on any commercial products. In addition, Lilly invested $15 million in NextCure equity.
-
NextCure Appoints Kevin N. Heller, M.D., as Chief Medical Officer and Steve Cobourn, CPA, as Chief Financial Officer
4/4/2018
Both are accomplished executives with proven track records in building biopharmaceutical companies.